NGM and Janssen to develop diabetes drugs
The two companies sign a worldwide agreement
NGM Biopharmaceuticals, a privately held drug discovery company located in South San Francisco, CA, US, has signed a worldwide agreement with Janssen Pharmaceuticals to develop new drugs for the potential treatment of Type 2 diabetes and other metabolic diseases.
The two companies will jointly conduct research on selected protein factors discovered by NGM using its diabetes discovery platform, with the aim of advancing drug candidates that mimic the potential glucoregulatory effects of bariatric surgery on diabetes patients.
Janssen will receive an exclusive worldwide license to develop, manufacture and commercialise compounds resulting from the collaboration.
Under the terms of the agreement, NGM will receive an upfront payment and research support for activities conducted in collaboration with Janssen. In addition, NGM is eligible to receive milestone payments, as well as royalties on worldwide product sales.
